Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development stage include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for tourette syndrome schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men?s and women?s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other con
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-11.83%||ROE||-12.96%||ROI|
|Current Ratio||22.19||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.04|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||275.28 M||Cash From Investing Activities||-170.01 M||Cash From Operating Activities||-4.22 M||Gross Profit|
|Net Profit||-23.99 M||Operating Profit||-25.32 M||Total Assets||511.2 M||Total Current Assets||389.42 M|
|Total Current Liabilities||17.55 M||Total Debt||560 K||Total Liabilities||44.27 M||Total Revenue|
|High 52 week||125.85||Low 52 week||68.88||Last close||71.98||Last change||1%|
|RSI||22.01||Average true range||5.04||Beta||1.39||Volume||828.99 K|
|Simple moving average 20 days||-13.45%||Simple moving average 50 days||-25.65%||Simple moving average 200 days||-27.66%|
|Performance Week||-2.51%||Performance Month||-20%||Performance Quart||-38.69%||Performance Half||-32.09%|
|Performance Year||2%||Performance Year-to-date||-7.23%||Volatility daily||4.02%||Volatility weekly||8.98%|
|Volatility monthly||18.41%||Volatility yearly||63.77%||Relative Volume||252.57%||Average Volume||1.13 M|
|New High||New Low|
2019-01-16 16:01:00 | New INGREZZA® valbenazine Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders
2019-01-16 06:57:11 | 4 Defensive Stocks to Buy Amid Shutdown and Brexit
2019-01-15 16:48:00 | Here’s your guide to the upcoming biotechnology takeover wave
2019-01-14 08:00:00 | Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences
2019-01-11 16:25:40 | Biotech Stocks Are Enjoying Their Best-Ever Start to the Year
2019-01-11 13:32:26 | Is Neurocrine Biosciences, Inc.’s NASDAQ:NBIX CEO Overpaid Relative To Its Peers?
2019-01-10 12:07:29 | 5 Biotech Stocks That Could Face M&A Next!
2019-01-09 08:05:22 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-01-08 08:15:37 | Why Neurocrine Biosciences Stock Rose 9.6% Yesterday
2019-01-07 12:42:05 | Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
2019-01-07 07:15:46 | Neurocrine Biosciences Is a Pharma Stock to Watch
2019-01-07 06:50:00 | Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Loxo Oncology
2019-01-06 10:56:42 | Neurocrine Biosciences Looks Oversold
2019-01-02 16:01:00 | Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
2018-12-31 07:51:00 | 4 of the Fastest Growing Biotech Stocks in 2019
2018-12-14 08:37:01 | Do Options Traders Know Something About Neurocrine Biosciences NBIX Stock We Don't?
2018-12-12 16:35:00 | Why Under Armour, Neurocrine Biosciences, and XPO Logistics Slumped Today
2018-12-12 12:49:00 | Why Neurocrine Biosciences Is Tanking
2018-12-12 12:19:54 | Why Neurocrine Biosciences Stock Is Plummeting Today
2018-12-12 07:39:00 | Neurocrine Biosciences says trial of Tourette syndrome treatment missed primary goal
2018-12-12 07:30:00 | Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
2018-12-09 03:31:14 | Should You Buy Neurocrine Biosciences, Inc. NBIX?
2018-12-06 08:03:22 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2018-12-04 08:03:22 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2018-11-27 08:04:43 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2018-11-27 07:15:00 | 3 Top Biotech Stocks to Buy Right Now
2018-11-16 09:04:02 | Neurocrine NBIX Catches Eye: Stock Jumps 6.5%
2018-11-12 15:16:52 | 5 Pharma Stocks to Stay Away From
2018-11-09 08:30:00 | Report: Developing Opportunities within Louisiana-Pacific, Neurocrine Biosciences, Tahoe Resources, Loews, Quotient Technology, and Evolent Health — Future Expectations, Projections Moving into 2018
2018-11-07 16:01:00 | Neurocrine Biosciences to Present at the Jefferies 2018 London Healthcare Conference
2018-11-07 12:17:39 | Does Neurocrine Biosciences Inc’s NASDAQ:NBIX Debt Level Pose A Problem?
2018-11-05 21:25:27 | Edited Transcript of NBIX earnings conference call or presentation 5-Nov-18 9:30pm GMT
2018-11-05 17:15:10 | Neurocrine Biosciences NBIX Q3 Earnings and Revenues Top Estimates
2018-11-05 16:11:15 | Neurocrine: 3Q Earnings Snapshot
2018-11-05 16:01:00 | Neurocrine Biosciences Reports Third Quarter 2018 Financial Results
2018-11-05 07:00:00 | Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Exelixis
2018-11-02 11:41:03 | Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
2018-10-31 10:25:02 | Neurocrine NBIX to Report Q3 Earnings: What's in the Cards?
2018-10-29 10:31:02 | Neurocrine Biosciences NBIX Q3 Earnings Preview: What to Look Out For
2018-10-25 15:05:02 | How Wall Street Analysts View Alkermes after Q3 Earnings Release
2018-10-25 12:01:41 | Alkermes in the Third Quarter: A Performance Overview
2018-10-23 16:01:00 | Neurocrine Biosciences to Present New Data Analyses on the Long-Term Effects of INGREZZA® valbenazine in Tardive Dyskinesia Patients with Mood Disorders at the 2018 Annual Psych Congress
2018-10-17 09:40:09 | How Acadia Pharmaceuticals Is Positioned Financially
2018-10-17 08:00:00 | Today's Research Reports on Trending Tickers: Lam Research and Applied Materials
2018-10-15 08:35:00 | New Research: Key Drivers of Growth for Neurocrine Biosciences, SS&C Technologies, Quaker Chemical, Sealed Air, KLA-Tencor, and Summit Hotel Properties — Factors of Influence, Major Initiatives and Sustained Production